ARCHIVES

Study Of Tamoxifen And Raloxifene Enrolls 6,000 In First Year; 5 Percent Are Minorities

This article is from The Cancer Letter archive.

Vol. 23 No. 7 | July 28, 2000

Download PDF Visit The Full Archive

Related Articles

Herceptin Regimen Minus Adriamycin Increases Survival With Less Toxicity

October 28, 2011

Cancer Panel To Examine Health Of Phase I Trials

May 17, 1996

Drug Development Committee Demands, Gets Greater Voice In Contract Awards, Review of Unsolicited Proposals, Suggests RFP For New Screening Systems

January 2, 1976

In Brief: Sullivan Will Be Secretary Most Knowledgeable About Cancer Program; Ihde Names ‘JNCI’ Editor

January 6, 1989

Sullivan Confirmation Hearing Set For Feb. 1

January 27, 1989

UPCI Clarifies Agreement Between Eli Lilly And PCRN.

July 27, 2001